Ultragenyx Pharmaceutical RARE Deferred Taxes
Deferred Taxes at other companies
Other financials
Where this comes from
Reported directly by Ultragenyx Pharmaceutical in its filing.
Tagged under the XBRL concept us-gaap:DeferredIncomeTaxLiabilitiesNet.
The official record: Ultragenyx Pharmaceutical’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ultragenyx Pharmaceutical's deferred taxes.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ultragenyx Pharmaceutical's deferred taxes?
- Ultragenyx Pharmaceutical (RARE) reported deferred taxes of $30M in Q1 2026.
- How has Ultragenyx Pharmaceutical's deferred taxes changed year-over-year?
- Ultragenyx Pharmaceutical's deferred taxes decreased by 0.2% year-over-year, from $30.06M to $30M.
- What is the long-term trend for Ultragenyx Pharmaceutical's deferred taxes?
- Over 5 years (2020 to 2025), Ultragenyx Pharmaceutical's deferred taxes has grown at a -2.1% compound annual growth rate (CAGR), from $33.31M to $30M.
- What does deferred taxes mean?
- This represents the net amount of income taxes that will be payable in future periods due to temporary differences between the carrying amount of assets and liabilities for financial reporting and their tax bases. It reflects the long-term tax impact of accounting choices and depreciation schedules. Investors use this to understand future tax obligations and the impact of tax timing on cash flow.